Fust Matthew K
SEC insider (Form 3/4/5 filer). CIK 0001397266. Director at Electra Therapeutics, Inc. (ETRA) and 4 other issuers. 31 reported Form 4/5 transactions since Sep 2024; latest on Sep 1, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies Fust Matthew K has filed insider reports for
- Electra Therapeutics, Inc. (ETRA): Director
- Crinetics Pharmaceuticals, Inc. (CRNX): Director
- Atara Biotherapeutics, Inc. (ATRA): Director
- Neumora Therapeutics, Inc. (NMRA): Director
- Ultragenyx Pharmaceutical Inc. (RARE): Director
Fust Matthew K
CIK: 0001397266
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (31 total)
- Sep 1, 2026CRNX
Crinetics Pharmaceuticals, Inc.
DispositionDirect5.9K shares at avg. $85.00$504K - Sep 1, 2026CRNX
Crinetics Pharmaceuticals, Inc.
DispositionDirect22.8K shares at avg. $85.00$1.9M - Jun 18, 2026CRNX
Crinetics Pharmaceuticals, Inc.
AwardDirect5.9K shares- - Jun 9, 2026ATRA
Atara Biotherapeutics, Inc.
AwardDirect12K shares- - May 27, 2026NMRA
Neumora Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
80K shares- - May 14, 2026RARE
Ultragenyx Pharmaceutical Inc.
AwardDirect7.8K shares- - Sep 26, 2025CRNX
Crinetics Pharmaceuticals, Inc.
ExerciseDirect10K shares at avg. $1.91$19K - Sep 26, 2025CRNX
Crinetics Pharmaceuticals, Inc.
SaleDirect16K shares at avg. $44.75$716K - Jun 11, 2025CRNX
Crinetics Pharmaceuticals, Inc.
AwardDirect6.9K shares- - Jun 10, 2025ATRA
Atara Biotherapeutics, Inc.
AwardDirect7.8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 1, 2026 |  CRNX Crinetics Pharmaceuticals, Inc. | Disposition | 5,925 | $85.00 | $503,625 | Direct |
| Sep 1, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Disposition | 22,836 | $85.00 | $1,941,060 | Direct |
| Jun 18, 2026 | CRNX Crinetics Pharmaceuticals, Inc. | Award | 5,925 | - | $0 | Direct |
| Jun 9, 2026 |  ATRA Atara Biotherapeutics, Inc. | Award | 12,000 | - | $0 | Direct |
| May 27, 2026 |  NMRA Neumora Therapeutics, Inc. | Award Stock Option (Right to Buy) | 80,000 | - | - | Direct |
| May 14, 2026 |  RARE Ultragenyx Pharmaceutical Inc. | Award | 7,751 | - | $0 | Direct |
| Sep 26, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | Exercise | 10,000 | $1.91 | $19,100 | Direct |
| Sep 26, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | Sale | 16,000 | $44.75 | $716,000 | Direct |
| Jun 11, 2025 | CRNX Crinetics Pharmaceuticals, Inc. | Award | 6,900 | - | - | Direct |
| Jun 10, 2025 | ATRA Atara Biotherapeutics, Inc. | Award | 7,828 | - | - | Direct |
1-10 of 31 transactions